Related Experiment Videos
Sensor Array for Detection of Early Stage Parkinson's Disease before Medication
John P M Finberg1, Miguel Schwartz2, Raneen Jeries3
1Neuroscience Department, Bruce Rappaport Faculty of Medicine , Technion - Israel Institute of Technology , Haifa 3200003 , Israel.
ACS Chemical Neuroscience
|July 11, 2018
Summary
This study introduces a novel electronic sensor array for early Parkinson's disease (PD) detection in untreated patients. The breath analysis system shows promise for real-world screening, distinguishing PD from controls with 81% accuracy.
Area of Science:
- Neuroscience
- Biomarker Discovery
- Medical Diagnostics
Background:
- Early diagnosis of Parkinson's disease (PD) is crucial for effective therapy selection and initiating neuroprotective treatments before significant neurodegeneration.
- Current methods for PD detection using volatile biomarkers have primarily focused on treated patients, necessitating studies on untreated individuals for accurate screening technology.
- There is a significant need for reliable diagnostic tools to identify de novo PD patients, enabling timely intervention.
Purpose of the Study:
- To evaluate an electronic sensor array system for detecting volatile molecules in exhaled breath to distinguish de novo Parkinson's disease (PD) patients from healthy controls.
- To assess the diagnostic performance of the breath sensor array compared to established methods like midbrain ultrasonography and smell detection.
- To investigate the association between breath volatile biomarkers and other common PD diagnostic tests, including nonmotor symptoms.
Main Methods:
- A clinical trial was conducted involving 29 de novo PD patients and 19 age-matched control subjects.
- An electronic sensor array system was employed to analyze volatile molecules present in the exhaled breath of participants.
- Diagnostic performance metrics (sensitivity, specificity, accuracy) were calculated for the sensor array and compared with midbrain ultrasonography and smell detection tests.
Main Results:
- The breath sensor array demonstrated a sensitivity of 79%, specificity of 84%, and accuracy of 81% in distinguishing PD patients from controls.
- Midbrain ultrasonography achieved higher diagnostic performance with 93% sensitivity, 90% specificity, and 92% accuracy.
- Smell detection showed a sensitivity of 62%, specificity of 89%, and accuracy of 73%.
Conclusions:
- The study confirms the potential of sensor array technology for the early detection of Parkinson's disease using exhaled breath.
- Breath analysis via sensor arrays offers a promising, non-invasive approach for real-world screening and diagnosis of PD.
- While sensor arrays show potential, midbrain ultrasonography currently exhibits superior diagnostic accuracy for PD detection in this cohort.